This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy
by Zacks Equity Research
Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy are included in this Analyst Blog.
Top Analyst Reports for Johnson & Johnson, Zoetis & Lam Research
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Zoetis (ZTS) and Lam Research Corporation (LRCX).
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results
by Zacks Equity Research
Bayer (BAYRY) lowers its full-year financial performance guidance for 2023 and reports preliminary earnings results for the second quarter of 2023.
4 Stocks to Buy Following Beat-and-Raise Quarters
by Derek Lewis
These companies beat expectations and raised their outlooks, undeniably a positive sign for investors. Is it time to buy following the better-than-expected results?
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
by Zacks Equity Research
In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Reasons Why Growth Investors Shouldn't Overlook Johnson & Johnson (JNJ)
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses solid growth attributes, which could help it handily outperform the market.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity.
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.
ETFs to Tap Dow Jones' Longest Winning Streak Since 2017
by Sweta Killa
Dow Jones climbed for nine consecutive sessions, marking the longest winning streak since Sep 20, 2017.
5 ETFs to Buy on JNJ's Q2 Earnings Strength
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.
Stock Market News for Jul 21, 2023
by Zacks Equity Research
Wall Street closed mixed on Thursday following mixed earnings results of second-quarter 2023.
Stocks in Focus on Dow Jones ETF's First 9-Day Run Since 2017
by Sanghamitra Saha
The Dow Jones index jumped more than 150 points on Jul 20, to log its first nine-day rally since 2017
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.
Weekly Jobless Claims Below Expectations
by Zacks Equity Research
Weekly Jobless Claims Below Expectations.
Q2 Beats for J&J, American; Jobless Claims, Philly Fed Lower
by Mark Vickery
Both J&J and American Airlines put up solid beats on top and bottom lines, while the labor market remains buoyant.
Here's What Key Metrics Tell Us About Johnson & Johnson (JNJ) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Johnson & Johnson (JNJ) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 7.28% and 3.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPLV
J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment, recovery in surgical procedures and new product launches are likely to have pushed sales growth.
3 Quarterly Reports Investors Can't Ignore This Week
by Derek Lewis
We've got a loaded slate, including quarterly results from Netflix, American Express, and Johnson & Johnson. But how do estimates stack up heading into their respective prints?